Malignant hyperthermia (MH) is a pharmacogenetic condition whereby in susceptible individuals, a rapid hypermetabolic response results from skeletal muscle calcium dysregulation 1 . Current studies into MH are limited by the utility of nonhuman skeletal muscle models or human non-skeletal muscle cell lines such as HEK-293 cells 2, 3 . Furthermore, experiments that use primary human tissue are inherently limited because of the rapid onset of replicative senescence that has been observed 4 . Thus, there is a crucial need to develop methods that will extend the life of cells derived from patients who are susceptible to MH (MHS) and their non-susceptible relatives (MHN) in order to allow an improved understanding of the mechanisms that underlie the pathophysiology of the human MH reaction. This study aims to develop such human skeletal muscle cell lines derived from patients with unique mutations associated with MH as well as those from their MHN relatives. Human biopsy samples taken for the diagnostic in vitro contracture tests were processed as previously described to isolate human myoblasts 5 . Myoblasts from three MHS patients, three MHN family members and a non-related MHN individual, were infected using the g-retroviral system to deliver genes encoding CDK-4 (cyclin dependent kinase) and hTERT (human telomerase reverse transcriptase). Successfully infected cells were selected using both puromycin (0.3 mg/ml) and hygromycin (50 mg/ml) for at least two weeks. Cells were then allowed to proliferate to over 10 doublings before undergoing fluorescent activated cell sorting (FACS) for CD56 and CD82 antigens in order to produce monoclonal and polyclonal pure myoblast cell lines. Myoblasts from two MHS patients and four MHN patients survived dual antibiotic selection for at least two weeks. These cells proliferated from approximately 10 000 cells to over one million cells prior to undergoing FACS, following which they were clonally expanded. All immortalised samples were found to contain cells positive for both CD56 and CD82, a combination which has recently been reported to be a marker of myoblasts that are able to differentiate into myotubes 6 .
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The immortalisation of these six primary human samples from MHS and MHN patients is novel the best of our knowledge. The cells are currently undergoing further characterisation in order to produce a regenerative pool of cells that will have the ability to replicate by more than 100 doublings and potentially providing over 1 Malignant hyperthermia (MH) is a progressive hypermetabolic reaction that occurs in genetically susceptible patients in response to triggering anaesthetic agents: the inhalation anaesthetics and the depolarizing muscle relaxant, succinylcholine. Index cases may be referred for testing because they developed features suggestive of a hypermetabolic MH reaction: a severe hypermetabolic reaction can progress to muscle rigidity and rhabdomyolysis. Other index cases are referred because they developed exaggerated muscle rigidity following succinylcholine or unexplained postoperative rhabdomyolysis, both of which are more common in individuals who are susceptible to MH. Our main aim was to identify the effect of the use of different anaesthetic drugs on the development of variable clinical features of MH. We included MH probands who were tested susceptible to MH using the in vitro contracture test (IVCT) between 1988 and 2017. Data were collected from copies of anaesthetic and perioperative records (where available), referral letters and copies of laboratory test results stored in the Leeds MH unit archive. We recorded the patient's age, sex, medical and anaesthetic history, details of drugs administered during anaesthesia, and the timing, nature and severity of clinical features associated with MH.
We collected data on 343 index cases, while 23 patients were excluded because of insufficient information. The mean age-at-episode of the included 320 patients was 24 years (range 2e74) and 66.9% (214 of 320) were males. In our cohort, 119 patients presented with both metabolic and muscular manifestations, 155 patients with hypermetabolic manifestations only and 46 patients presented with muscular rigidity. The reaction was triggered by both succinylcholine and inhalation agents in 171 patients, succinylcholine only in 53 patients and inhalation anaesthetics only in 96 patients.
Non-depolarising muscle relaxants (NDMR) were used in 95 patients and its use was associated with a statistically significant lower creatine kinase level, nevertheless, no significant effect of the use of NDMR on reducing the incidence of myoglobinuria or generalised muscular rigidity could be noticed. Four patients who received succinylcholine but no inhalational agent developed one or more features possibly suggesting a hypermetabolic MH reaction but alternative causes cannot be excluded because of a lack of information.
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